Interaction of nanoparticles with the pulmonary surfactant system
- PMID: 19558240
- DOI: 10.1080/08958370903005744
Interaction of nanoparticles with the pulmonary surfactant system
Abstract
Nano-sized particles (NSPs) have a diameter of less than 100 nm. When inhaled, they preferentially deposit in the deeper lung, where pulmonary surfactant covers the thin aqueous lining layer. Thus, pulmonary surfactant is the initial contact where NSPs impinge. This can lead to various consequences. For example, binding of NSPs to single surfactant components like phospholipids or surfactant proteins can occur, which might modulate toxic particle effects. Moreover, particle clearance can be modulated. Furthermore, the biophysical surfactant function itself can be disturbed by interaction with NSPs. In addition, surfactant displaces particles into the aqueous hypophase of the lining layer, where they can come into contact with type II pneumocytes. This interaction has been suggested to affect pulmonary surfactant metabolism. The potential interactions of nano-sized particles with the pulmonary surfactant system and the effects on biophysical surfactant function, surfactant metabolism, particle clearance, and on particle-induced toxicity are reviewed.
Similar articles
-
Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles.Inhal Toxicol. 1996;8 Suppl:73-89. Inhal Toxicol. 1996. PMID: 11542496 Review.
-
Effects of concentrated ambient particles on normal and hypersecretory airways in rats.Res Rep Health Eff Inst. 2004 Aug;(120):1-68; discussion 69-79. Res Rep Health Eff Inst. 2004. PMID: 15543855
-
Engineered nanoparticle respiratory exposure and potential risks for cardiovascular toxicity: predictive tests and biomarkers.Inhal Toxicol. 2009 Jul;21 Suppl 1:68-73. doi: 10.1080/08958370902942566. Inhal Toxicol. 2009. PMID: 19558236
-
Interaction of metal oxide nanoparticles with lung surfactant protein A.Eur J Pharm Biopharm. 2011 Apr;77(3):376-83. doi: 10.1016/j.ejpb.2010.10.013. Epub 2010 Nov 5. Eur J Pharm Biopharm. 2011. PMID: 21056657
-
Health effects of inhaled engineered and incidental nanoparticles.Crit Rev Toxicol. 2009;39(8):629-58. doi: 10.1080/10408440903133788. Crit Rev Toxicol. 2009. PMID: 19743943 Review.
Cited by
-
Allergen particle binding by human primary bronchial epithelial cells is modulated by surfactant protein D.Respir Res. 2010 Jun 22;11(1):83. doi: 10.1186/1465-9921-11-83. Respir Res. 2010. PMID: 20569420 Free PMC article.
-
Modeling In Vivo Interactions of Engineered Nanoparticles in the Pulmonary Alveolar Lining Fluid.Nanomaterials (Basel). 2015 Sep;5(3):1223-1249. doi: 10.3390/nano5031223. Nanomaterials (Basel). 2015. PMID: 26240755 Free PMC article.
-
Computational multiscale toxicodynamic modeling of silver and carbon nanoparticle effects on mouse lung function.PLoS One. 2013 Dec 3;8(12):e80917. doi: 10.1371/journal.pone.0080917. eCollection 2013. PLoS One. 2013. PMID: 24312506 Free PMC article.
-
The role of natural processes and surface energy of inhaled engineered nanoparticles on aggregation and corona formation.NanoImpact. 2016 Apr;2:38-44. doi: 10.1016/j.impact.2016.06.002. Epub 2016 Jun 11. NanoImpact. 2016. PMID: 29202111 Free PMC article.
-
Pulmonary surfactant is indispensable in order to simulate the in vivo situation.Part Fibre Toxicol. 2013 Mar 25;10:6. doi: 10.1186/1743-8977-10-6. Part Fibre Toxicol. 2013. PMID: 23531298 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources